Financials Akoya Biosciences, Inc.
Equities
AKYA
US00974H1041
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.79 USD | -3.79% | -32.12% | -42.83% |
02:12pm | Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating | MT |
05-14 | Top Midday Decliners | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 569.7 | 363.2 | 239.5 | 143.2 | - | - |
Enterprise Value (EV) 1 | 489 | 363.2 | 230.9 | 152 | 135.9 | 143.2 |
P/E ratio | -9.28 x | -5.12 x | -3.41 x | -2.64 x | -4.8 x | -9.89 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 10.4 x | 4.85 x | 2.48 x | 1.33 x | 1.1 x | 0.91 x |
EV / Revenue | 8.91 x | 4.85 x | 2.39 x | 1.41 x | 1.04 x | 0.91 x |
EV / EBITDA | -14.1 x | -6.12 x | -4.66 x | -4.87 x | -12.9 x | 53.2 x |
EV / FCF | -11.9 x | -5.97 x | -4.23 x | -5.13 x | -30.9 x | -43.4 x |
FCF Yield | -8.42% | -16.8% | -23.6% | -19.5% | -3.24% | -2.3% |
Price to Book | 4.72 x | 6.17 x | 4.03 x | 5.68 x | 8.62 x | 6.23 x |
Nbr of stocks (in thousands) | 37,208 | 37,956 | 49,076 | 49,386 | - | - |
Reference price 2 | 15.31 | 9.570 | 4.880 | 2.900 | 2.900 | 2.900 |
Announcement Date | 22-03-14 | 23-03-06 | 24-03-04 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 42.44 | 54.92 | 74.86 | 96.63 | 108.1 | 130.7 | 157.7 |
EBITDA 1 | - | -34.57 | -59.37 | -49.6 | -31.2 | -10.55 | 2.69 |
EBIT 1 | - | -39.3 | -66.11 | -57.67 | -40.82 | -23.1 | -5.302 |
Operating Margin | - | -71.56% | -88.31% | -59.68% | -37.77% | -17.67% | -3.36% |
Earnings before Tax (EBT) 1 | - | -43.08 | -70.52 | -63.28 | -49.45 | -27.18 | -14.2 |
Net income 1 | -16.71 | -44.37 | -70.64 | -63.32 | -51.61 | -32.33 | -14.7 |
Net margin | -39.36% | -80.79% | -94.37% | -65.53% | -47.76% | -24.74% | -9.32% |
EPS 2 | -9.180 | -1.650 | -1.870 | -1.430 | -1.097 | -0.6043 | -0.2933 |
Free Cash Flow 1 | - | -41.16 | -60.86 | -54.55 | -29.65 | -4.4 | -3.3 |
FCF margin | - | -74.95% | -81.29% | -56.45% | -27.44% | -3.37% | -2.09% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 21-03-26 | 22-03-14 | 23-03-06 | 24-03-04 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 16.16 | 16.89 | 17.89 | 18.85 | 21.22 | 21.41 | 23.52 | 25.22 | 26.49 | 18.35 | 24.66 | 29.31 | 34 | 27.26 | 30.41 |
EBITDA 1 | -15.41 | -14.01 | -14.69 | -14.84 | -15.83 | -15.46 | -17.4 | -9.176 | -7.565 | - | -8.682 | -4.03 | -1.601 | -5.968 | -3.666 |
EBIT 1 | -16.78 | -15.55 | -16.31 | -16.65 | -17.59 | -17.44 | -19.24 | -11.55 | -9.439 | -15.17 | -11.5 | -7.616 | -4.512 | -9.647 | -7.87 |
Operating Margin | -103.85% | -92.07% | -91.14% | -88.34% | -82.9% | -81.44% | -81.81% | -45.81% | -35.64% | -82.68% | -46.63% | -25.99% | -13.27% | -35.39% | -25.88% |
Earnings before Tax (EBT) 1 | -17.79 | -16.38 | -17.39 | -17.85 | -18.9 | -18.77 | -20.78 | -12.9 | -10.82 | -23.42 | -13.45 | -9.176 | -6.232 | -10.77 | -9.131 |
Net income 1 | -17.67 | -16.4 | -17.5 | -17.87 | -18.88 | -18.8 | -20.8 | -12.92 | -10.8 | -23.48 | -13.91 | -9.887 | -6.957 | -11.65 | -9.851 |
Net margin | -109.38% | -97.07% | -97.77% | -94.8% | -88.95% | -87.82% | -88.44% | -51.22% | -40.78% | -127.98% | -56.39% | -33.74% | -20.46% | -42.75% | -32.4% |
EPS 2 | -0.4700 | -0.4400 | -0.4700 | -0.4700 | -0.5000 | -0.4900 | -0.5100 | -0.2600 | -0.2200 | -0.4800 | -0.2850 | -0.1900 | -0.1400 | -0.2167 | -0.1733 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22-03-14 | 22-05-05 | 22-08-08 | 22-11-07 | 23-03-06 | 23-05-08 | 23-08-07 | 23-11-08 | 24-03-04 | 24-05-13 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 8.75 | - | - |
Net Cash position 1 | - | 80.6 | - | 8.57 | - | 7.29 | 0.05 |
Leverage (Debt/EBITDA) | - | - | - | - | -0.2804 x | - | - |
Free Cash Flow 1 | - | -41.2 | -60.9 | -54.6 | -29.7 | -4.4 | -3.3 |
ROE (net income / shareholders' equity) | - | -126% | -78.5% | -113% | -107% | -118% | -12.9% |
ROA (Net income/ Total Assets) | - | -33% | -38.5% | -35.5% | -25.3% | -13.9% | -4.3% |
Assets 1 | - | 134.3 | 183.5 | 178.2 | 203.8 | 232.3 | 341.9 |
Book Value Per Share 2 | - | 3.240 | 1.550 | 1.210 | 0.5100 | 0.3400 | 0.4700 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 5.09 | 7.36 | 3.65 | 5.9 | 6.75 | 7.4 |
Capex / Sales | - | 9.28% | 9.83% | 3.78% | 5.46% | 5.17% | 4.69% |
Announcement Date | 21-03-26 | 22-03-14 | 23-03-06 | 24-03-04 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.83% | 143M | |
+12.85% | 227B | |
+13.88% | 192B | |
+18.39% | 136B | |
+28.78% | 108B | |
+1.67% | 64.07B | |
+18.24% | 52.1B | |
+7.04% | 51.87B | |
+10.83% | 44.33B | |
+5.94% | 36.75B |
- Stock Market
- Equities
- AKYA Stock
- Financials Akoya Biosciences, Inc.